Is capecitabine a new choice of treatment for lung adenocarcinoma? A case report involving partial response in second line of treatment and hypothesis of the biological basis
Clin. transl. oncol. (Print)
; 11(8): 554-557, ago. 2009. ilus
Artigo
em Inglês
| IBECS
| ID: ibc-123676
Biblioteca responsável:
ES1.1
Localização: BNCS
ABSTRACT
In lung cancer different histologies have different biologies. Active agents in non-small-cell lung cancer (NSCLC) include platinums, paclitaxel, docetaxel, gemcitabine, erlotinib, pemetrexed and vinorelbine. We report a case of a patient with metastatic lung adenocarcinoma with high levels of LDH and CEA with clear partial response to capecitabine after several lines of chemotherapy. The increase in thymidine phosphorylase (TP) expression in NSCLC could provide a rationale for the use of capecitabine in this tumour. More research is needed to try to explain the striking activity of capecitabine in this patient with lung adenocarcinoma and high levels of CEA and to find molecular targets to predict the response to this agent (AU)
Buscar no Google
Coleções:
Bases de dados nacionais
/
Espanha
Base de dados:
IBECS
Assunto principal:
Adenocarcinoma
/
Desoxicitidina
/
Fluoruracila
/
Neoplasias Pulmonares
/
Antimetabólitos Antineoplásicos
Tipo de estudo:
Estudo prognóstico
Limite:
Humanos
/
Masculino
Idioma:
Inglês
Revista:
Clin. transl. oncol. (Print)
Ano de publicação:
2009
Tipo de documento:
Artigo
Instituição/País de afiliação:
Hospital Ruber Internacional/Spain